EventsThe 2nd International Electronic Conference on Vaccines
Published
This submission belongs to the session S1. Cancer Vaccines, Immunotherapy, and Immunoprevention of the event The 2nd International Electronic Conference on Vaccines
Published date
25 Nov, 2024
Academic Editor
author-avatarMona Mohsen
Citation
Xuelan Liu, Xinyue Chang, Zhenyuan Zhang, Fei Fei, Yilian Chen, Minghui Zhang, An attractive vaccine candidate based on AP205 VLPs fusing with an RBM domain of a new porcine deltacoronavirus strain in China, in Proceedings of The 2nd International Electronic Conference on Vaccines, 27 November–29 November 2024, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

An attractive vaccine candidate based on AP205 VLPs fusing with an RBM domain of a new porcine deltacoronavirus strain in China

Zhenyuan Zhang 1
Fei Fei 1
Yilian Chen 1
Minghui Zhang 1
1. College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China, China
Abstract

Swine coronaviruses (SeCoV) have become a major concern in pig farming and have caused enormous economic losses all over the world. Porcine deltacoronavirus (PDCoV) is a newly emerged SeCoV, which was able to infect avians as well as humans. Therefore, developing efficient vaccines against PDCoV is not only important to pork production, but also contributes to public healthcare. In this study, we identified a new PDCoV strain, CHN/GD/2023, which was isolated from a diarrheal piglet colon. After a thorough sequence analysis of the Spike gene, CHN/GD/2023 was found to be closely related with other PDCoV viruses that have recently been isolated in China. Next, a VLP-based vaccine candidate, AP205-RBD, was produced by genetically fusing the receptor-binding domain (RBD) of CHN/GD/2023 to the C-terminus of the AP205 gene. The purified AP205-RBD successfully displayed RBD on the surface and exhibited a spherical particle structure with a diameter of 51 nm. The agarose gel image demonstrated that ssRNA from E. coli was packaged inside the AP205-RBD particle. In addition, AP205-RBD demonstrated potent immunogenicity in mice, as highly RBD-specific IgG titers were detected. Importantly, these antibodies were able to neutralize CHN/GD/2023 PDCoV in vitro, suggesting that the AP205-RBD vaccine is capable of protecting against viruses. Moreover, we surprisingly found that AP205-RBD elicited antibodies that could neutralize another strain of PDCoV that was previously isolated in China, implying that AP205-RBD could potentially protect animals from different PDCoV strains. In summary, a new PDCoV strain was isolated and identified in this study, and an effective vaccine candidate, AP205-RBD, was reported, which could induce broad antibody protection responses in mice.

Keywords
Virus-like particles
AP205-VLPs
Porcine deltacoronavirus
Receptor-binding domain
Broad protection
Comparative immunogenicity of 10 µg versus 20 µg of Hepatitis B vaccine booster dose in healthcare workers
Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant